Physician profile
Craig E Sylte
NPI 1770712903
$1,505.00
in general payments reported to CMS, 2019-2025
14 companies · $181 in 2025
The $181 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $248 · 2020: $101 · 2022: $621 · 2023: $176 · 2024: $178 · 2025: $181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $535.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $535.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lkc Technologies, INC. | $598.00 | 2022 | |
| Alcon Vision LLC | $271.01 | 2019-2025 | Precision 7, Total30, Precision7 |
| Johnson & Johnson Vision Care, INC. | $135.45 | 2019-2025 | |
| Shire North American Group INC | $103.01 | 2019 | |
| Allergan, INC. | $101.12 | 2020 | |
| Novartis Pharmaceuticals Corporation | $85.06 | 2019-2023 | |
| Oyster Point Pharma, INC. | $65.08 | 2023-2025 | Tyrvaya, Ryzumvi |
| Dompe US, INC. | $36.16 | 2025 | Oxervate |
| Ani Pharmaceuticals, INC. | $31.69 | 2025 | Purified Cortrophin Gel |
| Abbvie INC. | $18.20 | 2023 | Alphagan P, Vuity, Lumigan |
| Tarsus Pharmaceuticals, INC. | $16.00 | 2025 | Xdemvy |
| Coopervision INC. | $15.61 | 2023 | Myday Contact Lens |
| Ocular Therapeutix, INC. | $14.66 | 2025 | Dextenza |
| Bausch & Lomb Americas INC. | $13.95 | 2024 | Infuse |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Craig Sylte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.